Anxiety disorders are a group of disorders that share symptoms like excessive fear and heightened stress (American Psychological Association [APA], 2022). It is important to note that fear and anxiety ...

- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Definium Therapeutics, Inc. (“Definium” or the “Company”), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world ...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR ...

Generalized anxiety disorder (GAD) is a type of excessive worrying that consumes the lives of people who experience it. Symptoms can include fatigue, headaches, shortness of breath, and having a hard ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

Findings highlight the link between anxiety severity and SI, underscoring the need for routine screening NEW YORK--(BUSINESS WIRE)-- Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the ...

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States The annual ...